← Back to Dr. Lal Path Labs Ltd. overview
Dr. Lal Path Labs Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹2,461 cr | ₹487 cr | ₹29.2 | ₹2,717 cr | ₹2,173 cr | 22.42% | 27.77% | 0.07x | 19.79% |
| FY2024 | ₹2,227 cr | ₹358 cr | ₹21.49 | ₹2,456 cr | ₹1,849 cr | 19.34% | 25.51% | 0.13x | 16.07% |
| FY2023 | ₹2,017 cr | ₹239 cr | ₹14.37 | ₹2,386 cr | ₹1,666 cr | 14.33% | 18.28% | 0.25x | 11.84% |
| FY2022 | ₹2,087 cr | ₹345 cr | ₹20.79 | ₹2,353 cr | ₹1,508 cr | 22.86% | 24.75% | 0.35x | 16.52% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.